Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
February 10, 2025 09:15 ET
|
IMAC Holdings, Inc.
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of...
IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
January 27, 2025 16:10 ET
|
IMAC Holdings, Inc.
Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary dedicated to...
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
November 22, 2024 17:15 ET
|
IMAC Holdings, Inc.
FRANKLIN, TN, Nov. 22, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it received an expected deficiency notification letter from the...
IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)
November 14, 2024 09:10 ET
|
IMAC Holdings, Inc.
FRANKLIN, TN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it has received an exception from the Listing Qualifications Staff...
IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology
September 19, 2024 10:00 ET
|
IMAC Holdings, Inc.
Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative healthcare solutions, proudly announces the launch of...
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
August 23, 2024 17:20 ET
|
IMAC Holdings, Inc.
FRANKLIN, TN, Aug. 23, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it received an expected deficiency notification letter from the...
IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors
July 11, 2024 09:21 ET
|
IMAC Holdings, Inc.
Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ: BACK) (the “Company” or “IMAC”), a leading innovator in proteomics research and technology, announced the appointment of...
IMAC Holdings Announces Leadership Succession
May 24, 2024 09:00 ET
|
IMAC Holdings, Inc.
Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”) today announced leadership transitions to the...
IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business
May 07, 2024 08:30 ET
|
IMAC Holdings, Inc.
FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ:...
IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
September 27, 2023 16:30 ET
|
IMAC Holdings, Inc.
Franklin, TN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”) today announced that it has received notice from The Nasdaq Stock Market LLC informing...